Consolidated Statements of Operations (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Revenue
Tissue sales	$ 34,569,160	$ 32,563,933
Royalties and other	762,652	509,481
Total Revenue	35,331,812	33,073,414
Cost of sales	13,034,314	14,185,719
Gross Profit	22,297,498	18,887,695
Operating Expenses
General and administrative	8,886,972	10,204,659
Sales and marketing	16,912,865	16,017,229
Research and development	1,443,018	572,361
Depreciation and amortization	271,748	377,524
Impairment of assets	912,549	728,618
Non-cash consulting expense	135,075	(5,117)
Total Operating Expenses	28,562,227	27,895,274
Loss from Operations	(6,264,729)	(9,007,579)
Other Income (Expense)
Interest expense	(5,660,357)	(4,653,232)
Change in warrant derivative liability	1,736,053	875,041
Other (expense)	(318,836)	92,645
Total Other Income (Expense)	(4,243,140)	(3,685,546)
Net Loss from Operations Before (Provision) Benefit for Income Taxes	(10,507,869)	(12,693,125)
(Provision) Benefit for Income Taxes
Current	0	0
Deferred	0	0
Net Loss	$ (10,507,869)	$ (12,693,125)
Net loss per share:
Basic (in dollars per share)	$ (1.76)	$ (2.80)
Dilutive (in dollars per share)	$ (1.76)	$ (2.80)
Shares used in the computation:
Basic (in shares)	5,954,195	4,530,072
Dilutive (in shares)	5,954,195	4,530,072